AR058855A1 - Compuestos heterociclicos que se unen a proteinas bcl inhibiendo su funcion, composiciones farmaceuticas que los contienen y usos para el tratamiento del cancer - Google Patents

Compuestos heterociclicos que se unen a proteinas bcl inhibiendo su funcion, composiciones farmaceuticas que los contienen y usos para el tratamiento del cancer

Info

Publication number
AR058855A1
AR058855A1 ARP060105561A ARP060105561A AR058855A1 AR 058855 A1 AR058855 A1 AR 058855A1 AR P060105561 A ARP060105561 A AR P060105561A AR P060105561 A ARP060105561 A AR P060105561A AR 058855 A1 AR058855 A1 AR 058855A1
Authority
AR
Argentina
Prior art keywords
independently
heteroaryl
heterocyclyl
aryl
formula
Prior art date
Application number
ARP060105561A
Other languages
English (en)
Original Assignee
Infinity Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Pharmaceuticals Inc filed Critical Infinity Pharmaceuticals Inc
Publication of AR058855A1 publication Critical patent/AR058855A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms

Abstract

Reivindicacion 1: Un compuesto representado por la formula (1): o una sal farmacéuticamente aceptable del mismo; en la cual Y es -C(R10)2-, -(C=O)-, -(C=S)-, o -C(=NR10)-; X es -N(R10)- o un enlace; m es 0, 1, 2, 3, 4, 5 o 6; cada uno de A1 y A2 es independientemente H, alquilo, alquenilo, alquinilo, arilo, cicloalquilo, aralquilo, heterociclilo, heteroarilo, heteroaralquilo, -C(O)N(R10)2, -C(O)R10, -CO2R10, -S(O)2N(R10)2, -S(O)R10, -S(O)2OR10, -S(O)2R10; o tiene la formula -(C(R10)2)n-R15: en la cual, independientemente para cada ocurrencia n es 1, 2, 3, 4, 5 o 6; R15 es arilo, cicloalquilo, cicloalquenilo, heterociclilo, heteroarilo, -OR10, -SR10, -N(R10)2, -N(R10)CO2R10, -N(R10)C(O)N(R10)2, -CO2R10 o -C(O)N(R10)2; o es un anillo policíclico que contiene C8-14, del cual por lo menos uno, dos o tres átomos del anillo son independientemente S, O o N; o A1 y A2 tomados conjuntamente forman =O o =S; o A1 y A2 tomados conjuntamente con el carbono al cual están unidos forman un heterociclilo de 5 a 8 miembros, del cual uno o dos átomos del anillo son independientemente S, O o N; B es O, S, -(C=O)-, -(C=S)- o es un resto de formula (2); o tiene la formula (3): en la cual D es N o CR10; p es 0, 1, 2, 3, 4 o 5; cada uno de R7 y R8 es, independientemente para cada ocurrencia, H, alquilo, alquenilo, alquinilo, aralquilo, arilo, cicloalquilo, heterociclilo, cicloalquenilo o heteroarilo; o R7 y R8 tomados conjuntamente forman un anillo de 3-8 miembros; o R7 y R8 tomados conjuntamente forman un anillo de 4-8 miembros; R9 es H, heterociclilo, heteroarilo, -OR10, -SR10, -N(R10)2, -N(R10)CO2R10, -N(R10)C(O)N(R10)2, -CO2R10, -OCO2R10, -OC(O)N(R10)2, -C(O)N(R10)2, haluro, nitrilo, nitro o aciltio; R1 tiene la formula (4): en la cual q es 0, 1, 2, 3, 4 o 5; r es 0, 1, 2, 3, 4 o 5; Ar1 es un arilo monocíclico o bicíclico con 6-14 átomos en el anillo; o un heteroarilo monocíclico o bicíclico con 5-14 átomos en el anillo, del cual uno, dos o tresátomos del anillo son independientemente S, O o N; o Ar1 está representado por la formula (5): en la cual s es 0, 1, 2, 3 o 4; cada uno de X2 y X3 es, independientemente para cada ocurrencia, H, alquilo, alquenilo, alquinilo, arilo, cicloalquilo, heterociclilo, aralquilo, heteroarilo, heteroaralquilo, hidroxilo, aciloxi, nitrilo, nitro, haluro, OR11, -C(O)N(R10)(R11), -C(O)R11, -CO2R11, -S(O)2N(R10)(R11), SR11, -S(O)R11, -S(O)2OR11, -S(O)2R11, -C(=NR10)N(R10)(R11) o -C(=NR10)(R11); o tiene la formula - (C(R10)2)n-R15; Ar2 es un arilo monocíclico o bicíclico con 6-14 átomos en el anillo; o un heteroarilo monocíclico o bicíclico con 5-14 átomos en el anillo, del cual uno, dos o tres átomos del anillo son independientemente S, O o N; X1 es un enlace, -C(R10)2-, -S-, -(NR10)- o -O-; R2 es H, un alquilo o alquenilo ramificado o no ramificado, cicloalquilo, heterociclilo o bicicloalquilo; o tiene la formula -(C(R10)2)n-R15; R3 es H, heterociclilo, heteroarilo, -OR10, -SR10, -N(R10)2, -N(R10)CO2R10, -N(R10)C(O)N(R10)2, -CO2R10, -OCO2R10, -OC(O)N(R10)2, -C(O)N(R10)2, haluro, nitrilo, nitro o aciltio; cada uno de R4, R5 y R10, independientemente para cada ocurrencia, es H, alquilo, alquenilo, alquinilo, aralquilo, arilo, cicloalquilo, cicloalquenilo, bicicloalquilo, heterociclilo o heteroarilo; o tiene la formula -(C(R10)2)n-R15; o cualesquiera dos casos de R10 tomados conjuntamente forman un anillo de 3-8 miembros; o R4 y R5 tomados conjuntamente forman un anillo de 3-8 miembros; R6 es H o alquilo; R11 es, independientemente para cada ocurrencia, H, alquilo, alquenilo, alquinilo, aralquilo, arilo, cicloalquilo, cicloalquenilo, bicicloalquilo, heterociclilo, heteroarilo o -[C(R12)(R13)]t-R14; en donde t es 0, 1, 2, 3, 4 o 5; cada uno de R12 y R13 es independientemente para cada ocurrencia, H, alquilo, arilo, aralquilo, cicloalquilo, heterociclilo, heterociclilalquilo, heteroarilo o heteroaralquilo; yR14 es independientemente para cada ocurrencia, H, alquilo, arilo, heteroarilo, heterociclilalquilo, alcoxi, amino, amido, o carboxilo.
ARP060105561A 2005-12-16 2006-12-15 Compuestos heterociclicos que se unen a proteinas bcl inhibiendo su funcion, composiciones farmaceuticas que los contienen y usos para el tratamiento del cancer AR058855A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75098705P 2005-12-16 2005-12-16

Publications (1)

Publication Number Publication Date
AR058855A1 true AR058855A1 (es) 2008-02-27

Family

ID=38024107

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105561A AR058855A1 (es) 2005-12-16 2006-12-15 Compuestos heterociclicos que se unen a proteinas bcl inhibiendo su funcion, composiciones farmaceuticas que los contienen y usos para el tratamiento del cancer

Country Status (27)

Country Link
US (2) US7745464B2 (es)
EP (1) EP1973875B1 (es)
JP (1) JP5341521B2 (es)
KR (1) KR101373911B1 (es)
CN (1) CN101374807B (es)
AR (1) AR058855A1 (es)
AU (1) AU2006329879B2 (es)
BR (1) BRPI0619968A2 (es)
CA (1) CA2633958C (es)
EC (1) ECSP088607A (es)
ES (1) ES2494765T3 (es)
HK (1) HK1119704A1 (es)
IL (1) IL192023A (es)
JO (1) JO2918B1 (es)
MA (1) MA30144B1 (es)
MX (1) MX2008007687A (es)
MY (1) MY153232A (es)
NO (1) NO20083050L (es)
NZ (1) NZ569660A (es)
PE (1) PE20071033A1 (es)
RU (1) RU2424230C2 (es)
SA (1) SA06270462B1 (es)
SG (1) SG170727A1 (es)
TN (1) TNSN08258A1 (es)
TW (1) TWI403320B (es)
WO (1) WO2007075387A1 (es)
ZA (1) ZA200805822B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842815B2 (en) * 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
TWI389895B (zh) * 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
US7858666B2 (en) 2007-06-08 2010-12-28 Mannkind Corporation IRE-1α inhibitors
CN101906056B (zh) * 2009-06-04 2013-10-30 中国科学院广州生物医药与健康研究院 作为m2抑制剂的环烷胺类化合物及其应用
US8314250B2 (en) * 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
FR3048698B1 (fr) * 2016-03-11 2021-03-05 Univ Claude Bernard Lyon Inhibiteurs de l'interaction bcl2 l10 / recepteur ip3
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR900012875A (ko) * 1989-02-08 1990-09-03 오스카 아끼히꼬 비페닐 유도체, 신경세포 변성수복 또는 보호제 및 여기에 사용되는 폐닐유도체의 제조방법
BR9408137A (pt) 1993-11-24 1997-08-12 Du Pont Merck Pharma Composto éster de prodroga método de tratamento composição farmacêutica e método de inibição
US6693123B2 (en) * 1995-11-06 2004-02-17 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
KR100399361B1 (ko) * 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
EP1125925A1 (en) * 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
AU2001252222B2 (en) * 2000-03-27 2006-11-02 Merck Serono Sa Pharmaceutically active pyrrolidine derivatives as bax inhibitors
AU2001284942A1 (en) 2000-08-16 2002-02-25 Georgetown University Medical Center Small molecule inhibitors targeted at bcl-2
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US7855183B2 (en) * 2000-11-10 2010-12-21 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US20040147473A1 (en) * 2000-11-10 2004-07-29 Warrell Raymond P. Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
DE60237115D1 (de) 2001-05-30 2010-09-02 Univ Georgetown Synergistische Kombination von (-) -Gossypol mit Docetaxel oder Paclitaxel zur Behandlung von Krebs.
US20030119894A1 (en) 2001-07-20 2003-06-26 Gemin X Biotechnologies Inc. Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells
AU2003223708A1 (en) * 2002-04-23 2003-11-10 Axys Pharmaceuticals, Inc. Novel phenyl derivatives as inducers of apoptosis
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
MXPA05002573A (es) * 2002-09-04 2005-09-08 Schering Corp Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
JP2006516250A (ja) * 2002-12-18 2006-06-29 サイトビア インコーポレイティッド カスパーゼ活性化剤およびアポトーシス誘導物質としての３，５−二置換−［１，２，４］−オキサジアゾールおよびそれらの誘導体ならびにそれらの使用
US20040242886A1 (en) * 2003-04-30 2004-12-02 Sandeep Gupta Monocyclic diazodioxide based Bcl-2 protein antagonists related applications
CA2526387A1 (en) * 2003-06-12 2004-12-23 Astellas Pharma Inc. Benzamide derivative or salt thereof
WO2005026156A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
ES2339670T3 (es) * 2003-12-23 2010-05-24 Novartis Ag Inhibidores heterociclicos biciclicos de la quinasa p-38.
TW200528101A (en) * 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
PL1768966T3 (pl) 2004-06-17 2012-08-31 Infinity Discovery Inc Związki i sposoby hamowania oddziaływania białek BCL z partnerami wiążącymi
WO2006025360A1 (ja) 2004-08-30 2006-03-09 Mitsubishi Rayon Co., Ltd. 光学用共重合体及びそれからなる成形体
TW200626142A (en) * 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
US7759337B2 (en) * 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
TW200803740A (en) * 2005-12-16 2008-01-16 Du Pont 5-aryl isoxazolines for controlling invertebrate pests
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
BRPI0619968A2 (pt) 2011-10-25
JP5341521B2 (ja) 2013-11-13
MA30144B1 (fr) 2009-01-02
EP1973875B1 (en) 2014-06-11
JP2009519946A (ja) 2009-05-21
WO2007075387A1 (en) 2007-07-05
SG170727A1 (en) 2011-05-30
TNSN08258A1 (en) 2009-10-30
KR101373911B1 (ko) 2014-03-12
CA2633958C (en) 2014-04-01
CN101374807A (zh) 2009-02-25
EP1973875A1 (en) 2008-10-01
NZ569660A (en) 2010-07-30
ES2494765T3 (es) 2014-09-16
US8304428B2 (en) 2012-11-06
SA06270462B1 (ar) 2011-10-03
CN101374807B (zh) 2013-10-09
TW200811100A (en) 2008-03-01
NO20083050L (no) 2008-09-10
JO2918B1 (en) 2015-09-15
MX2008007687A (es) 2008-09-26
AU2006329879A8 (en) 2008-08-07
MY153232A (en) 2015-01-29
TWI403320B (zh) 2013-08-01
AU2006329879A1 (en) 2007-07-05
HK1119704A1 (en) 2009-03-13
RU2008128569A (ru) 2010-01-27
US20100190791A1 (en) 2010-07-29
PE20071033A1 (es) 2007-11-26
IL192023A (en) 2014-06-30
RU2424230C2 (ru) 2011-07-20
US7745464B2 (en) 2010-06-29
ECSP088607A (es) 2008-08-29
AU2006329879B2 (en) 2012-06-21
ZA200805822B (en) 2009-03-25
CA2633958A1 (en) 2007-07-05
US20070155705A1 (en) 2007-07-05
IL192023A0 (en) 2008-12-29
KR20080077017A (ko) 2008-08-20

Similar Documents

Publication Publication Date Title
AR058855A1 (es) Compuestos heterociclicos que se unen a proteinas bcl inhibiendo su funcion, composiciones farmaceuticas que los contienen y usos para el tratamiento del cancer
ES2589555T3 (es) Compuestos de benceno sustituidos con arilo o heteroarilo
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
AR106944A2 (es) Compuestos de isoindolina y composiciones farmacéuticas de los mismos
AR085327A1 (es) Inhibidores del virus de la hepatitis c
AR060545A1 (es) Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas
CO6241190A2 (es) Compuestos para inhibicion enzimatica
AR084553A1 (es) DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER
AR091279A1 (es) Inhibidores macrociclicos de virus flaviviridae
ES2626555T3 (es) Pyridone amides como moduladores de canales de sodio
AR090398A1 (es) Inhibidores heterociclicos de glutaminasa
BRPI0619823A8 (pt) compostos que são inibidores de erk
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
CO6321289A2 (es) Compuestos de ester boronato y composiciones farmaceuticas de los mismos
AR087711A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y uso de los mismos para el tratamiento de trastornos neurodegenerativos
CO5261616A1 (es) Inhibidores no peptidicos de la union celular dependientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
CO4990929A1 (es) Compuestos de difenilurea sustituidos con sulfonamidas como antagonistas de los receptores de il-8
AR093758A1 (es) Inhibidores de aril lactama quinasa
AR054482A1 (es) Derivados de azetidinona para el tratamiento de hiperlipidemias
AR098666A1 (es) Compuestos de biarilacetamida y sus métodos de uso
AR090868A1 (es) Composiciones plaguicidas y procesos relacionados con ellas
AR083946A1 (es) Metodos de tratamiento con inhibidores selectivos de bcl-2
AR081653A1 (es) Inhibidores del virus de la hepatitis c
BR0114986A (pt) Composto, composição farmacêutica, uso de pelo menos um composto ou um sal, solvato ou hidrato deste farmaceuticamente aceitáveis, e, processo para preparar triazolona partir de uma acil semicarbazida.
CO6150158A2 (es) Piperidinas sustituidas que aumentan la actividad de p53 y su uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure